Summary & Overview
HCPCS C8002: Automated Skin Cell Suspension Autograft Preparation
HCPCS Level II code C8002 identifies the automated preparation of an autologous skin cell suspension for grafting, including enzymatic processing and device components. This code is significant nationally as advanced cell-based wound therapies and skin restoration techniques expand clinical use and raise payment, coding, and coverage questions across payer types.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise guide to what the code covers clinically, typical settings for service delivery, and the payer landscape relevant to coverage and billing. The publication outlines benchmarks and coding considerations, summarizes recent or relevant policy developments affecting cellular graft preparation services, and situates C8002 within broader trends in advanced wound care and biologic therapies.
The analysis delivers practical reference material for billing and coding staff, revenue cycle managers, and clinical leaders seeking clarity on documentation expectations, typical sites of service, and where to look for payer-specific guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C8002 describes the preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components. The service encompasses automated laboratory and device-based processing to create a suspension of skin cells for autologous grafting.
Service Type: Autologous skin cell suspension preparation (automated enzymatic processing)
Typical Site of Service: Hospital outpatient departments, specialized wound care centers, or ambulatory surgical centers where skin grafting and advanced biologic preparation are performed.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with a chronic non-healing full-thickness burn wound and large surface area loss of epidermis is evaluated in an outpatient burn reconstruction clinic. After conservative wound care and staged debridement, the multidisciplinary team determines the patient is a candidate for an autologous epidermal cell suspension autograft to promote re-epithelialization of areas not amenable to split-thickness skin grafting. The procedure involves harvesting a small donor skin sample, transporting it to an on-site automated processing device, and preparing a skin cell suspension autograft via enzymatic digestion and automated separation. The processed suspension is then applied to the recipient bed in the operating room or procedure suite.
Workflow:
-
Pre-procedure evaluation and consent in clinic, including documentation of wound characteristics, prior treatments, and donor site selection.
-
On the day of service, the donor site is prepared and a small punch or shave sample of epidermis/partial-thickness skin is obtained under local or general anesthesia.
-
The harvested tissue is handed to trained staff/technician who loads it into the automated device for enzymatic processing and suspension preparation covered by
C8002. -
While processing occurs (device run time may vary), the surgical team prepares the recipient wound bed (debridement, hemostasis, and wound bed optimization).
-
Once the automated suspension is ready, the clinician applies the
skin cell suspension autograftto the recipient site, secures dressings, and documents the processing method (automated) to justify use ofC8002(do not report with manual preparation). Postoperative instructions and follow-up plan are provided.